(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1349)
EXTRAORDINARY GENERAL MEETING
REPLY SLIP
To: Shanghai Fudan-ZhangjiangBio-Pharmaceutical Co., Ltd.* (the "Company")
I/we (note 1) (Chinese name)
(English name)
of
(as shown in the register of members) being the
registered holder(s) of (note 2)
H shares/domestic shares (note 3)
of RMB0.10 each in the capital of the Company, hereby inform the Company that I/we intend to attend (in person or by proxy) the extraordinary general meeting of the Company to be held at No. 308 Cailun Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai, the PRC at 10:00 a.m. on Monday, 28 October 2019.
Date:
2019
Signature(s):
Notes:
Please insert full name(s) and address(es) (as shown in the register of members) in BLOCK LETTERS.
Please insert the number of shares registered in your name(s).
Please delete the inappropriate.
In order to be valid, the completed and signed reply slip shall be delivered to the following addresses on or before Tuesday, 8 October 2019. This reply slip may be delivered to the Company by hand, by post or by facsimile.
For holders of domestic shares:
No. 308 Cailun Road, Zhangjiang Hi-tech Park
Pudong New Area, Shanghai, the PRC (Postal Code: 201210)
Fax: (8621) 5855 3893
For holders of H shares:
17M Floor, Hopewell Centre
183 Queen's Road East, Hong Kong Fax: (852) 2865 0990
For identification purpose only
Attachments
Original document
Permalink
Disclaimer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. published this content on 12 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 September 2019 09:21:12 UTC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.